Results 91 to 100 of about 3,225,863 (285)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of ...
Moran Hausman‐Kedem +9 more
wiley +1 more source
Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms [PDF]
, 2015 Objective In primary care, assessing which patients with bowel symptoms harbour significant disease (cancer, higher-risk adenoma or IBD) is difficult.
Wilson, Robyn +6 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper +7 more
wiley +1 more source
High Health Care Utilization Preceding Diagnosis With Juvenile Idiopathic Arthritis
Arthritis Care &Research, EarlyView.Objective Although early diagnosis improves long‐term outcomes, patients with juvenile idiopathic arthritis (JIA) often experience prolonged, circuitous paths to diagnosis. To inform diagnostic improvement, we sought to characterize health care utilization in the year preceding diagnosis. Methods We identified 10,021 patients with an incident diagnosis
Anna Costello +5 more
wiley +1 more source
Unreliable information and fear: Barriers to vaccination among IBD patients in China
Human Vaccines & ImmunotherapeuticsVaccination plays a crucial role in safeguarding individuals with inflammatory bowel disease (IBD) from potential epidemics. In light of the resurgence of COVID-19 in China, unvaccinated IBD patients are vulnerable to infection and potentially serious ...
Jingwen Liu +4 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications ...
Francesca Ruffilli +10 more
wiley +1 more source
Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease [PDF]
, 2008 AIM:To investigate the efficacy of 6-mercaptopurine (6-MP) in cases of azathioprine (AZA) hypersensitivity in patients with inflammatory bowel disease. METHODS: Twenty nine previously confirmed Crohn’s disease (CD) (n = 14) and ulcerative colitis (UC)
Nagy, Ferenc +5 more
core +1 more source
The Full Picture of Ulcerative Colitis: The Burden, the Patient, the Treatment [PDF]
European Medical Journal Gastroenterology, 2015 Ulcerative colitis (UC) carries a significant, progressive disease burden that is often underestimated or misinterpreted by healthcare providers. Adverse outcomes have a major impact on patient quality of life, with a significant burden of symptoms both ...
Julián Panés +2 more
doaj
Arthritis Care &Research, EarlyView.Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source
Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) [PDF]
Background: The utilization of anti-tumor necrosis factor-alpha (anti-TNF-alpha) biosimilars in inflammatory bowel disease (IBD) is constantly increasing. However, pediatric data are limited.
Francesco Graziano +21 more
core +1 more source